Advertisement

Topics

Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial

20:44 EST 13 Nov 2017 | FinanzNachrichten

BASEL (dpa-AFX) - Novartis (NVS) announced results from a new analysis of the Phase III CANTOS study. The pre-planned secondary analysis of an exploratory endpoint showed that people with a prior ...

Original Article: Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial

NEXT ARTICLE

More From BioPortfolio on "Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...